OMNICELL,INC. (NASDAQ:OMCL) Files An 8-K Entry into a Material Definitive Agreement

0

OMNICELL,INC. (NASDAQ:OMCL) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01 Entry into a Material Definitive Agreement.

On November3, 2017, Omnicell,Inc. (the “Company”) entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and HSBC Securities (USA) Inc., as its sales agents (the “Sales Agents”), to which the Company may offer and sell from time to time through the Sales Agents up to $125,000,000 maximum aggregate offering price of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), in such amounts as the Company may specify by notice to any Sales Agent, in accordance with the terms and conditions set forth in the Distribution Agreement.

Sales, if any, of the Common Stock to the Distribution Agreement may be made in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule415 under the Securities Act, including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange. The Company is not obligated to sell any Common Stock under the Distribution Agreement.

The Distribution Agreement contains customary representations, warranties and agreements of the Company, indemnification rights and obligations of the parties, and termination provisions. Under the terms of the Distribution Agreement, the Company has agreed to indemnify the Sales Agents against certain specified types of liabilities, including liabilities under the Securities Act of 1933, as amended, to contribute to payments the Sales Agents may be required to make in respect of these liabilities, and to reimburse the Sales Agents for certain expenses. In the ordinary course of business, the Sales Agents or their respective affiliates from time to time have provided and may in the future provide various investment banking, commercial banking and financial advisory services to the company and/or its affiliates, for which they have received or may receive customary compensation.

The Company intends to use the net proceeds from the sale, if any, of Common Stock in the offering for general corporate purposes, which may include, without limitation, the acquisition of complementary businesses, the repayment of outstanding indebtedness, capital expenditures and working capital.

The above summary of the Distribution Agreement does not purport to be complete and is qualified in its entirety by reference to the Distribution Agreement, a copy which is attached as Exhibit1.1 to this Current Report on Form8-K and incorporated herein by reference.

Item 9.01 Other Events.

A copy of the opinion of Cooley LLP with respect to the validity of the shares of Common Stock that may be sold and issued to the Distribution Agreement is attached as Exhibit5.1 to this Current Report on Form8-K. This Current Report on Form8-K is also being filed for the purpose of filing Exhibits 5.1 and 23.1 as exhibits to the Company’s effective Registration Statement on FormS-3 (Registration No.333-221332) and such exhibits are hereby incorporated by reference into such Registration Statement.

Item 9.01

Financial Statements and Exhibits.

(d)Exhibits.


OMNICELL, Inc Exhibit
EX-1.1 2 a17-24980_4ex1d1.htm EX-1.1 Exhibit 1.1   DISTRIBUTION AGREEMENT   November 3,…
To view the full exhibit click here

About OMNICELL,INC. (NASDAQ:OMCL)

Omnicell, Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment organizes the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. Its product line includes OmniRx, SinglePointe, AnywhereRN, Omnicell and Pandora Data Analytics, Savvy Mobile Medication System, Central Pharmacy and Satellite Pharmacy Manager, Anesthesia Workstation and Advanced Interoperability products.